MEDI-528, now recognized as enokiizumab , represents a groundbreaking treatment targeting the insulin-like growth factor 1 receptor , a key protein linked in several epidermal conditions . Early clinical data suggest considerable efficacy for the lessening of substantial eczema , particularly in those who have not benefited from previous remedies.